This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Active Biotech To Present At The Jefferies 2013 Global Healthcare Conference

LUND, Sweden, Nov. 14, 2013 (GLOBE NEWSWIRE) --

Active Biotech (NASDAQ OMX NORDIC: ACTI) is
scheduled to present at the Jefferies Global Healthcare Conference held November
20-21, 2013 in London, UK. During the presentation, an update regarding Active
Biotech's development programs will be provided.

The presentation will include the laquinimod project, a novel oral
immunomodulatory drug primarily for the treatment of multiple sclerosis,
licensed to Teva Pharmaceutical, the Phase III prostate cancer project
tasquinimod in co-development with Ipsen, as well as ANYARA, Active Biotech's
novel concept for tumor therapy of primarily renal cell cancer. Also, the
project with paquinimod (57-57) and the pre-clinical ISI project will be
presented.

The audio and slide presentation will be webcasted live and can be accessed via
the Active Biotech web site. To access the live and replay presentations please
go to - www.activebiotech.com.

The presentation will take place on November 20, at 08:00 a.m. GMT (Greenwich
Mean Time) / 09:00 am Central European Time.

For further information, please contact:
Hans Kolam, CFO
Phone: +46 (0)46 19 20 44
E-mail: hans.kolam@activebiotech.com



Active Biotech AB (NASDAQ OMX NORDIC: ACTI) is a biotechnology company with
focus on autoimmune/inflammatory diseases and cancer. In pivotal phase is
laquinimod, an orally administered small molecule with unique immunomodulatory
properties for the treatment of multiple sclerosis. Also tasquinimod for the
treatment of prostate cancer, with a unique mode of action, is in pivotal phase.
In addition, laquinimod has concluded Phase II development for Crohn's and
Lupus. The company has two additional projects in clinical development, ANYARA
primarily for the treatment of renal cell cancer and the orally administered
compound paquinimod (57-57) for systemic sclerosis. Please visit
www.activebiotech.com for more information.

Active Biotech AB (Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund
Tel: +46 46 19 20 00
Fax: +46 46 19 11 00

Active Biotech is obligated to publish the information contained in this press
release in accordance with the Swedish Securities Market Act. This information
was provided to the media for publication 8:30 a.m. CET on November 14, 2013.


Active Biotech to Present at the Jefferies 2013 Global Healthcare Conf: http://hugin.info/1002/R/1742843/586064.pdf

[HUG#1742843]

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,826.30 -279.47 -1.54%
S&P 500 2,081.18 -23.81 -1.13%
NASDAQ 4,931.8150 -75.9760 -1.52%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs